Abecma (idecabtagene vicleucel)

News alerts, weekly reports and conference planners

Company:

2seventy bio, BMS

Drug class:

BCMA-targeted CAR-T immunotherapy

Related drugs:

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	idecabtagene vicleucel Sensitive: A1 - Approval idecabtagene vicleucel Sensitive : A1	idecabtagene vicleucel Sensitive: A1 - Approval idecabtagene vicleucel Sensitive : A1
TNFRSF17 deletion	Multiple Myeloma	TNFRSF17 deletion	Multiple Myeloma	idecabtagene vicleucel Resistant: C4 – Case Studies idecabtagene vicleucel Resistant : C4	idecabtagene vicleucel Resistant: C4 – Case Studies idecabtagene vicleucel Resistant : C4

Associations
(2)